Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers
The IARC count for 2018: about 18.1 million new cancer cases worldwide, with lung cancer the most commonly diagnosed and most lethal, and about one in five men and one in six women developing cancer during their lifetime.
Overview
GLOBOCAN 2018 estimated cancer incidence and mortality for 36 cancers in 185 countries from national and regional registries and modelling. It counted 18.1 million new cases in 2018. Lung cancer was the most commonly diagnosed cancer and the leading cause of cancer death, followed for incidence by female breast, colorectal and prostate cancers. The report described how cancer patterns differ with a country's level of development, with infection-related cancers of the cervix, liver and stomach concentrated in transitioning economies.
- About 18.1 million new cancer cases and 9.6 million cancer deaths worldwide in 2018.
- Lung cancer the most commonly diagnosed (11.6% of cases) and the leading cause of cancer death (18.4% of deaths); female breast cancer also 11.6% of cases; colorectal 10.2%; prostate 7.1%.
- About one in five men and one in six women develop cancer during their lifetime; one in eight men and one in eleven women die from it.
This was the most cited description of the global cancer burden until the 2020 release and is the reference behind many national cancer plans of the late 2010s. Its country-level comparisons showed where prevention, such as HPV and hepatitis B vaccination and tobacco control, would have the largest effect.
- Registry coverage is incomplete in much of Africa and Asia, so those estimates depend on modelling.
- Superseded by the 2020 and 2022 releases.
CONCORD is the evidence base for national cancer plans and for the statement that where you live changes your chance of surviving cancer. Its country tables are the benchmark health systems use to judge early diagnosis and treatment access.
GBD is the other major global cancer count alongside GLOBOCAN, using different methods, and its burden measures in years of life lost make the case that cancer control is largely a problem of ageing populations in middle-income countries.
China accounts for roughly a quarter of the world's cancer cases, and this paper is the reference that made its burden legible internationally. It explains why Chinese trial programmes and drug pipelines concentrate on lung, stomach, oesophageal and liver cancers.
One of the most cited descriptions of the global cancer burden of the 2010s, it framed the shift of cancer towards lower-income countries that later GLOBOCAN releases have confirmed.
Similar pages
not linked directly; found by shared links- Key paperSiegel 2024: Cancer statistics, 2024, the American Cancer Society's annual US report
Shares Bray 2024: GLOBOCAN 2022, the world's cancer count for 36 cancers in 185 countries, Incidence versus prevalence, Mortality, Prostate cancer.
- TermPrognosis
Shares Allemani 2018: CONCORD-3, global surveillance of cancer survival 2000 to 2014, Incidence versus prevalence, Mortality.
- InstitutionNational Cancer Center of China
Shares Chen 2016: Cancer statistics in China, 2015, International Agency for Research on Cancer (IARC / WHO).
- InstitutionInstituto Nacional de Câncer (INCA)
Shares International Agency for Research on Cancer (IARC / WHO), Prostate cancer, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer.
- Key paperCalle 2003: overweight, obesity and death from cancer in 900,000 US adults
Shares Mortality, Colorectal cancer.
- TermAlcohol-attributable cancer
Shares International Agency for Research on Cancer (IARC / WHO), Colorectal cancer, HR-positive / HER2-negative breast cancer.
- InstitutionCancer Institute of Iran, Imam Khomeini Hospital Complex
Shares International Agency for Research on Cancer (IARC / WHO), Colorectal cancer, HR-positive / HER2-negative breast cancer.
- InstitutionInstitut Salah Azaïez
Shares International Agency for Research on Cancer (IARC / WHO), Colorectal cancer, HR-positive / HER2-negative breast cancer.